Skip to main content
Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
12.86
-1.56 (-10.82%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Avalo Therapeutics Revenue

In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%. Avalo Therapeutics had revenue of $59.00K in the quarter ending December 31, 2025, a decrease of -69.27%.

Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
5,822.82
Revenue / Employee
$1,788
Employees
33
Market Cap
343.55M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202559.00K-382.00K-86.62%
Dec 31, 2024441.00K-1.48M-77.08%
Dec 31, 20231.92M-16.13M-89.34%
Dec 31, 202218.05M12.65M234.40%
Dec 31, 20215.40M-1.30M-19.42%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Bicycle Therapeutics 72.59M
Opus Genetics 14.20M
Armata Pharmaceuticals 4.90M
Surrozen 3.48M
Compass Therapeutics 850.00K
Silence Therapeutics 559.00K
Revenue Rankings

AVTX News

More News